John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

The contribution of a sustained angiogenesis inhibition in metastatic colorectal cancer (mCCR) treatment. Introduction to maintenance concept beyond progression Volume 19, issue 7, Septembre 2012

Figures

See all figures

Authors
Institut de Cancérologie de l’Ouest, Bd J Monod, 44 805 Nantes, France, Hôpital Saint-Antoine, service d’oncologie médicale, Paris, France

This review traces a new concept of treatment in metastatic colo-rectal cancer called “sustained angiogenesis inhibition beyond progression”. In clinical practice, a multiline strategy is commonly defined, using each active drug in sequential therapeutic schedules. The clinical benefit demonstration of maintaining anti-angiogenic therapy beyond progression while switching chemotherapy across multiple lines allows to validate a new therapeutic strategy in mCCR.